SPN and diffuse large B-cell lymphoma: The 5‐year EFS rates for patients with CD43+ vs CD43− DLBCL were 25.8% vs 56.6%, respectively, and the 5‐year OS rates for patients with CD43+ vs CD43− DLBCL were 29.2% vs 61.9%, respectively.